Medtronic CoreValve® System Sustains Superior Survival Benefit Over Open Heart Surgery at Two Years

Medtronic plc (NYSE: MDT) today unveiled new, highly anticipated two-year data from the High Risk Study of the CoreValve U.S. Pivotal Trial, which continued to show superior survival benefit at two years for transcatheter aortic valve replacement (TAVR) with the CoreValve® System compared to patients who underwent surgical aortic valve replacement (SAVR). The CoreValve US Pivotal High Risk Study is the first and only head-to-head study to show statistically significant survival differences favoring TAVR in aortic stenosis patients who are considered high risk for surgery.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news